Bayer Names Figures Facts 2009 2010

Names | Figures | Facts
2009 | 2010
Contents
Cover picture
Bayer chemists Dr. Susanne Roehrig and
Dr. Alexander Straub examine the molecular
contours of rivaroxaban – the active ingre-
dient of the new anticoagulant Xarelto® –
using a computer simulation. One of Bayer’s
aims in developing this innovative drug is to
minimize the risk of thrombosis following
orthopedic surgery.
Bayer Names | Figures | Facts
Contents
Credo 2
Organization 4
Sites and Regions 6
Board of Management 8
Supervisory Board, Corporate Governance 10
Business Trends 12
Investor Information 14
Subgroups and Service Companies
Bayer HealthCare 16
Bayer CropScience 20
Bayer MaterialScience 24
Service Companies 28
Research and Development 30
Employees 32
Sustainability and Commitment 34
History 38
Dialogue 42
Masthead 45
2 Credo
Working to Create
Value through Inno-
vation and Growth
Bayer is a global enterprise with core competencies in
the fields of health care, nutrition and high-tech materi-
als. Our products and services are designed to benefit
people and improve their quality of life. At the same time
we want to create value through innovation, growth and
high earning power.
We are firmly aligned to our mission statement “Bayer:

Science For A Better Life” and continue to optimize our port-
folio, concentrating our activities in three high-potential, ef-
ficient subgroups with largely independent operations:
HealthCare, CropScience and MaterialScience. These provide
us with access to major global growth markets and are sup-
ported by our service companies.
As an inventor company, we plan to continue setting trends

in research-intensive areas. Innovation is the foundation for
competitiveness and growth, and thus for our company’s suc-
cess in the future.
Our expertise and our products are helping to diagnose, al-

leviate or cure diseases, improving the quality and adequacy
of the global food supply, and contributing significantly to an
active, modern lifestyle. Our expertise and innovative capabil-
ity also enable us to offer solutions for protecting the climate
and addressing the consequences of climate change.
We are committed to the principles of sustainable develop-

ment, and to our role as a socially and ethically responsible
corporate citizen. For us, there is a clear link between techni-
cal and economic expertise and our responsibility to work for
the benefit of humankind, become socially involved and make
a lasting contribution to sustainable development. At Bayer,
we regard economy, ecology and social commitment as ob-
jectives of equal rank.
Bayer Names | Figures | Facts 3
We seek to retain society’s confidence through performance,

flexibility and open communication as we work in pursuit of
our overriding goals: to steadily create corporate value and
generate high value-added for the benefit of our stockholders,
our employees and the community in every country in which
we operate.
www.bayer.com > Bayer Group > Mission Statement
Bayer AG headquarters in Leverkusen

4 Organization
Organization
Bayer AG defines common values, goals and strategies for

the entire Group. The three subgroups and three service com-
panies operate independently, led by the management hold-
ing company. The Corporate Center supports the Group Man-
agement Board in its task of strategic leadership.
Organization Chart
Bayer AG (holding company)
Group Management Board
Chairman Werner Wenning

Strategy & Human Resources Richard Pott*
Finance Klaus Kühn
Innovation, Technology Wolfgang Plischke

& Environment
Corporate Center Departments

Corporate Office Jörg Krell
Communications Michael Schade
Investor Relations Alexander Rosar
Corporate Auditing Rainer Meyer
Corporate Human Resources Jan Peters
& Organization
Finance Johannes Dietsch
Corporate Development Matthias Mangold
Law & Patents, Insurance Roland Hartwig
Environment & Sustainability Wolfgang Große Entrup
Group Accounting Ulrich Hauck
& Controlling
Regional Coordination Ian Paterson
* Labor Director
** The names “Bayer Schering Pharma” or “Schering” as used in this publication always refer to Bayer Schering
Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.
Business Areas
Bayer HealthCare
Chairman Arthur J. Higgins

Animal Health Lykele van der Broek
Consumer Care Gary Balkema
Medical Care Sandra E. Peterson
Bayer Schering Pharma** Andreas Fibig
Bayer Schering Pharma Business Units** Gunnar Riemann
Bayer Schering Pharma Regions ** Ulrich Köstlin
Bayer Schering Pharma Global Drug Discovery** Andreas Busch
Bayer Schering Pharma Global Development** Kemal Malik
Central Administration & Organization Werner Baumann*
Product Supply Hartmut Klusik
Bayer CropScience
Chairman Friedrich Berschauer

Portfolio Management Rüdiger Scheitza*
Research Alexander Klausener
Development Franz-Josef Placke
Industrial Operations & QHSE Wolfgang Welter
Business Planning & Administration Dirk Suwelack
Crop Protection Asia Pacific Bernd Naaf
Crop Protection Europe & TAMECIS Jacques du Puy
Crop Protection North America William Buckner
Crop Protection Latin America Marc Reichardt
Environmental Science Pascal Housset
BioScience Joachim Schneider
Bayer MaterialScience
Chairman Patrick Thomas

Administration Axel Steiger-Bagel
Industrial Operations Tony Van Osselaer*
Polycarbonates Günter Hilken
Polyurethanes Peter Vanacker
Coatings, Adhesives, Specialties Joachim Wolff
Region APAC Tim Bielfeldt
Service Areas
Bayer Business Services
Chairman of the Executive Board Daniel Hartert

Member of the Executive Board Norbert Fieseler*
Bayer Technology Services
Managing Director Achim Noack
Currenta
Chairman of the Executive Board Klaus Schäfer

Member of the Executive Board Joachim Waldi*
6 Sites and Regions
Sites and Regions
The Bayer Group is a

global enterprise with
companies in nearly every
country. The map shows
some of its principal sites.
North America
Sales €8,026 million (-1.7 %)*
Employees 17,000
R+D expenses €459 million
Companies 45**
Latin America/Africa/Middle East

Sales €4,958 million (+6.4 %)*
Employees 15,300
Companies 46**
* sales by market, percentage change from previous year (as of Dec. 31, 2008)
** fully consolidated subsidiaries (as of Dec. 31, 2008)
Europe
Sales €14,549 million (+1.4 %)*
Employees 55,500
R+D expenses €2,014 million
Companies 167**
Asia/Pacific
Sales €5,385 million, (+3.3 %)*
Employees 20,800
Companies 58**
www.bayer.com > Bayer Group > Bayer Worldwide

8 Board of Management of Bayer AG
Board of Management
of Bayer AG
Werner Wenning
Chairman of the Group Management
Board since April 2002. Born in 1946,
Werner Wenning joined the company
in 1966 as a commercial trainee. He
held a number of positions with Bayer
in Germany and abroad, serving as
managing director of Bayer subsidiar-
ies in Peru and Spain and later as Head
of the Corporate Planning and Control-
ling Division. Wenning was appointed
to the Board of Management as Chief
Financial Officer in February 1997. He
was President of the German Chemical
Industry Association from 2005 until
2007 and is currently its Vice Presi-
dent.
Dr. Wolfgang Plischke

Responsible for Innovation, Technology
and Environment and the Asia/Pacific
region. Born in 1951, Wolfgang Plischke
studied biology at Hohenheim Univer-
sity, Germany. Having gained his Ph.D.,
Plischke began his career with Bayer in
1980, joining the subsidiary Miles. After
holding a number of positions in Ger-
many and abroad, he became Head of
the Pharmaceuticals Business Group in
North America in 2000, and two years
later took charge of the Pharmaceuticals
Business Group of Bayer AG. Plischke
was appointed to the Bayer AG Board of
Management in March 2006. Since
December 2007, he has been Chairman
of the German Association of Research-
Based Pharmaceutical Companies.
Klaus Kühn
Chief Financial Officer and responsible
for the Europe region. Born in 1952,
Klaus Kühn studied mathematics and
physics at the Technical University of
Berlin, Germany, gaining a mathemat-
ics degree in 1978. He also studied in
the United States, where he obtained a
Master of Business Administration.
Kühn joined Bayer AG in 1998 as Head
of the Finance Section, and shortly af-
terwards was made Head of the Group
Finance Division. He was appointed to
the Bayer AG Board of Management in
May 2002.
Dr. Richard Pott

The member responsible for Strategy
and Human Resources and the Ameri-
cas, Africa and Middle East regions,
Dr. Richard Pott is also Bayer AG’s
Labor Director. Born in 1953, Richard
Pott studied physics at the University
of Cologne, Germany, where he ob-
tained his Ph.D. In 1984 Pott joined the
company’s Central Research Division.
After holding various positions in the
Corporate Staff Division he became
Head of the former Specialty Products
Business Group in 1999. He was ap-
pointed to the Bayer AG Board of
Management in May 2002.
10 Supervisory Board, Corporate Governance
Supervisory Board,
Corporate Governance
The role of Bayer AG’s 20-member Supervisory Board is to
oversee and advise the Board of Management. Under the
German Codetermination Act, half the members of the Su-
pervisory Board are elected by the stockholders, and half by
the company’s employees. The Supervisory Board is directly
involved in decisions on matters of fundamental importance
to the company and confers with the Board of Management
on the company’s strategic alignment. It also holds regular
discussions with the Board of Management on the company’s
business strategy and status of its implementation.
The Supervisory Board has set up four committees – the Pre-

sidial Committee, the Audit Committee, the Human Resourc-
es Committee and the Nominations Committee – and entrust-
ed them with certain tasks in accordance with the German
Stock Corporation Act and the German Corporate Governance
Code.
Corporate Governance
Bayer has always placed great importance on responsible
corporate governance. Last year the company was able to
renew its declaration that it is in full compliance with the
recommendations of the German Corporate Governance
Code.
Members of the Supervisory Board

Chairman of the Supervisory Board
Dr. Manfred Schneider
Vice Chairman of the Supervisory Board

Thomas de Win
Chairman of the Bayer Central Works Council, Leverkusen
Other members of the Supervisory Board

Dr. Paul Achleitner
Member of the Board of Management of Allianz SE, Munich
Willy Beumann
Chairman of the Works Council of the Wuppertal site of Bayer AG
Dr. Clemens Börsig
Chairman of the Supervisory Board of Deutsche Bank AG, Frankfurt am Main
Karl-Josef Ellrich
Chairman of the Dormagen Works Council of Bayer AG; Chairman of the Bayer Group Works Council
Dr.-Ing. Thomas Fischer
Chairman of the Bayer Group Managerial Employees’ Committee
Peter Hausmann
North Rhine District Secretary of the German Mining, Chemical and Energy Industrial Union, Düsseldorf
Prof. Dr.-Ing. e. h. Hans-Olaf Henkel
Honorary Professor at the University of Mannheim, Berlin
Reiner Hoffmann
Deputy General Secretary of the European Trade Union Confederation (ETUC), Brussels
Dr. rer. pol. Klaus Kleinfeld
Chief Executive Officer of ALCOA Inc., New York, USA
André Krejcik
Member of the Works Council of Bayer Schering Pharma AG
Petra Kronen
Chairwoman of the Uerdingen Works Council of Bayer AG
Dr. rer. nat. Helmut Panke
Member of various supervisory boards, Munich
Hubertus Schmoldt
Chairman of the German Mining, Chemical and Energy Industrial Union, Hannover
Dr.-Ing. Ekkehard D. Schulz
Chairman of the Executive Board of ThyssenKrupp AG, Duisburg/Essen
Dr. Klaus Sturany
Member of various supervisory boards, Essen
Dipl.-Ing. Dr.-Ing. e. h. Jürgen Weber
Chairman of the Supervisory Board of Deutsche Lufthansa AG, Cologne
Prof. Dr. Dr. h. c. Ernst-Ludwig Winnacker
Secretary General of the European Research Council, Brussels
Oliver Zühlke
Vice Chairman of the Bayer AG Works Council
Honorary Chairman
Hermann Josef Strenger
www.bayer.com > Bayer Group > Supervisory Board

www.bayer.com > Bayer Group > Corporate Governance
12 Business Trends
Business Trends
In 2008 Bayer had a successful year overall in an increas-

ingly difficult economic environment. The Group’s key op-
erational performance data showed a slight further improve-
ment from the previous year, and earnings targets were
achieved.
Group sales
Sales of the Bayer Group came in at €32,918 million, up
1.6 percent from the prior-year figure of €32,385 million. Ad-
justed for currency and portfolio effects, business expanded
by 4.4 percent. HealthCare posted a 6.9 percent increase on
a currency- and portfolio-adjusted basis. CropScience sales
climbed by 13.9 percent. MaterialScience experienced a con-
siderable drop in business in the fourth quarter as a result of
the financial and economic crisis, causing full-year sales to
drop by 4.6 percent.
Earnings
Group ebitda before special items rose by 2.3 percent to a
record €6,931 million. With an improvement in the ebitda
margin before special items to 21.1 percent, the Group met
its profitability target for fiscal 2008. The operating result
(ebit) before special items increased by 1.3 percent com-
pared with the previous year, to €4,342 million.
Gross cash flow increased by 10.7 percent from the previous

year to €5,295 million due to the gratifying business trend at
HealthCare and CropScience. Net cash flow declined by
15.7 percent to €3,608 million, mainly due to a significant
increase in cash tied up in working capital. Contributing to
this increase was a higher level of receivables and inventories
at HealthCare and CropScience, which was partly the result
of business growth.
Bayer Group Key Data

Bayer Group 2007 2008 Change
€ million € million in %
Sales 32,385 32,918 1.6

EBITDA1 5,866 6,266 6.8
EBITDA before special items 6,777 6,931 2.3
EBIT2 3,154 3,544 12.4
EBIT before special items 4,287 4,342 1.3
Income before income taxes 2,234 2,356 5.5
Net income 4,711 1,719 -63.5
Earnings per share (€)3 5.84 2.22 -62.0
Gross cash flow4 4,784 5,295 10.7
Net cash flow 5
4,281 3,608 -15.7
Capital expenditures* 1,891 1,982 4.8
Research and development expenses 2,578 2,653 2.9
Dividend per Bayer AG share (€) 1.35 1.40 3.7
* as per segment table in the Annual Report 2008

For notes see page 44
Sales by subgroup
Reconciliation
4.2 %
29.6 %
Bayer HealthCare
46.8 %
Bayer CropScience
19.4 %
Current information on business developments will be found on the Internet at:

www.financialreports.bayer.com
14 Investor Information
Investor Information
Caught up in the global market turbulence, Bayer stock lost

33.6 percent on the year. Including the dividend of €1.35 per
share paid in May 2008, its performance amounted to minus
31.9 percent. Despite the drop in the share price, Bayer
ranked among the top third of dax 30 stocks in performance
terms.
The price initially fell by some 25 percent at the start of the

year to €47 at the beginning of March. This was followed by
a rally that lasted until mid-September and restored the price
to about €57. The collapse of the investment bank Lehman
Brothers in mid-September was just one of the factors caus-
ing share prices around the world to plummet in the fourth
quarter. Amid very high trading volumes, especially in Octo-
ber (11.5 million shares per day), Bayer stock fell to a year
low of €36.83 on November 21, 2008.
German stock market

Last year saw the second-worst performance by the dax since
its introduction on July 1, 1988. The index closed 2008 at
4,810 points, down 40 percent from the end of the previous
year. Only in 2002 did it sustain a heavier loss of 44 per-
cent.
The downward movement was triggered by the subprime

mortgage crisis in the United States, which began in summer
2007. The resulting crisis on the financial markets eventually
spread to the real economy, leading to the current global
economic downturn. Nearly all dax companies saw double-
digit falls in their share prices.
Dividend per share

Subject to the approval of the Annual Stockholders’ Meeting,
the dividend will increase by 4 percent to €1.40, giving a total
dividend payment of €1,070 million and a dividend yield of 3.4
percent calculated on the 2008 year-end price.
Comparative performance of Bayer stock

indexed; 100 = closing price on December 31, 2007
110
100
90
80 -31,9 %
-40,4 %
70
-42,3 %
60
50
08 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Bayer DJ EURO STOXX 50SM DAX
Dividend data
Total dividend payment (€ million)
1,100 1,070
1,022 1,032
1,000 949
900
800 764
694
700 657 657
600
500
402
400 365
300
200
100
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Dividend per share (€)

1.30 1.40 0.90 0.90 0.50 0.55 0.95 1.00 1.35 1.40
www.investor.bayer.com
16 Subgroups | Bayer HealthCare
Bayer HealthCare
Bayer HealthCare is among the world’s foremost innovators

in the field of pharmaceutical and medical products. This
subgroup’s mission is to research, develop, manufacture and
market innovative products that improve the health of people
and animals throughout the world.
The subgroup has four operating divisions:
• Animal Health (veterinary medicines and grooming

products);
• Bayer Schering Pharma (prescription medicines);
• Consumer Care (over-the-counter medicines and dietary
supplements);
• Medical Care* (blood glucose monitoring devices and
contrast agent injection systems).
Business development
In 2008 Bayer HealthCare raised sales by 4.1 percent to
€15.4 billion. ebitda before special items rose by 9.6 percent
to €4.2 billion.
Sales of the Bayer Schering Pharma Division increased by

4.3 percent to €10.7 billion. The Consumer Care Division
grew sales in 2008 by 5.2 percent to €2.8 billion. Sales of the
Diabetes Care Division* advanced by 2.1 percent in 2008, to
€970 million. In the Animal Health Division, sales rose by
0.7 percent to €963 million.
* The Diabetes Care Division and the Medrad medical devices business were combined
to form the Medical Care Division effective January 1, 2009.
Corporate Data
Company name Bayer HealthCare AG
Headquarters Leverkusen, Germany
Chairman of the
Board of Management Arthur Higgins
Divisions Animal Health
Bayer Schering Pharma
Consumer Care
Diabetes Care*
Sales €15,407 million
EBITDA1 before special items €4,157 million
R&D expenses €1,742 million
Employees 53,100
(as of December 31, 2008)
Arthur Higgins,
Chairman of the Board
of Management
Sales
€ million
2008 15,407
2007 14,807
Number of employees
Employees
2008 53,100
2007 51,500
Research and development expenses

€ million
2008 1,742
2007 1,700
Current information on business developments will be found on the Internet at

18 Subgroups | Bayer HealthCare
Research and development activities

Research and development at Bayer HealthCare focus on
identifying and developing new active substances to treat
diseases with a high unmet medical need. In 2008 Bayer
HealthCare, with r&d spending of €1.7 billion, accounted for
66 percent of all r&d expenditures in the Bayer Group.
The Bayer Schering Pharma* Division carries out research

and product development mainly in the fields of Diagnostic
Imaging, Cardiology, Oncology and Women’s Healthcare.
Topical examples of active ingredients to emerge from phar-
maceutical research are:
• Xarelto®: Drug product for the prevention and treatment

of venous thromboembolism;
• Nexavar®: Anti-cancer medicine designed to inhibit
tumor growth by combining two special mechanisms of
action;
• vegf Trap-Eye: protein intended for use in the treatment
of eye diseases;
• Visanne®: Drug to treat endometriosis.
Research and development activities in the Consumer Care

Division focus on the identification, development and market
introduction of non-prescription products.
Research in the Medical Care Division is directed mainly to-

ward the development of user-friendly blood glucose measur-
ing devices that cater to the individual needs of people with
diabetes. The Division is also investing in technologies to
allow continuous blood glucose monitoring and, in the longer
term, to eliminate the need for blood sampling.
Research in the Animal Health Division is targeted toward

antibiotics, parasiticides and other active ingredients to treat
non-infectious conditions such as kidney disease, cardiovas-
cular disorders and cancer in companion animals.
* The names “Bayer Schering Pharma” or “Schering” as used in this publication always
refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG,
Berlin, Germany, respectively.
Best-selling products*
Adalat®
Drug for the treatment of hypertension
Advantage®
Line of flea control products for dogs and cats
Aspirin®
Pain reliever based on acetylsalicylic acid
Avalox®/Avelox®
Drug to treat respiratory infections
Betaferon®/Betaseron®
Specialty medicine to treat multiple sclerosis
Cipro®/Ciprobay®
Medicine to treat infectious diseases
Contour®
Umbrella brand for blood glucose monitoring systems and services
Kogenate®
Hemophilia treatment
Levitra®
Erectile dysfunction medicine
Mirena®
Hormonal contraceptive
Nexavar®
Drug to treat kidney and liver cancer
YAZ®/Yasmin®/Yasminelle®
Hormonal contraceptive
* in alphabetical order
Did you know that ...

Thomas Mann, winner of the
Nobel Prize for Literature, wrote
the following succinct entry in his
diary on February 25, 1918: “At
supper time I drank punch, which
warmed my feet, took Aspirin –
and I felt better”? Crime author
Raymond Chandler and thriller
writer Frederick Forsyth also gave
supporting roles in their stories to
the little white tablet that cel-
ebrates its 110th birthday in 2009.
www.bayerhealthcare.com
20 Subgroups | Bayer CropScience
Bayer CropScience
Bayer CropScience, with its highly effective products, pio-

neering innovations and keen customer focus, holds global
leadership positions in crop protection and non-agricultural
pest control. The company also has major activities in seeds
and crop plants with genetically optimized properties.
It is structured into six Business Operations units: four re-

gional Crop Protection units plus the Environmental Science
and BioScience units.
Sales of Bayer CropScience rose by a substantial 9.5 percent
in 2008, reaching the record level of €6.4 billion. The under-
lying conditions on the world agricultural markets were
highly favorable overall. Against the background of a steadi-
ly expanding global population with increasing nutritional
requirements, combined with low inventories worldwide and
heightened demand for plants as alternative energy sources,
very high prices for major agricultural products – particu-
larly in the first half of the year – led to higher investment by
farmers in high-quality seed and innovative crop protection
products. The subgroup not only increased volumes signifi-
cantly but also succeeded in raising prices, especially in its
Crop Protection business. The Crop Protection segment
boosted sales by 11.7 percent to €5.3 billion. Key growth
drivers were the young products based on active ingredients
introduced to core markets since 2000. Sales of these prod-
ucts climbed by some 36 percent to €1.8 billion.
Corporate Data
Company name Bayer CropScience AG
Headquarters Monheim, Germany
Chairman of the
Board of Management Friedrich Berschauer
Business groups Crop Protection
Environmental Science
BioScience
R&D expenses €649 million
Employees 18,300

Friedrich Berschauer,
of Management
Sales
€ million
2008 6,382
2007 5,826
Number of employees
Employees
2008 18,300
2007 17,800

€ million
2008 649
2007 637

22 Subgroups | Bayer CropScience
Im Environmental Science, sales receded in 2008 by 10.9

percent to €591 million, while in BioScience sales rose by
18.3 percent to €452 million.
ebitda before special items for the subgroup advanced by

21.1 percent to €1.6 billion. The significant improvement in
profitability was the result of the gratifying business trend.

In 2008, €649 million, or roughly 24 percent of the Bayer
Group’s research and development budget, was spent in the
CropScience subgroup.
Major areas of focus, apart from conventional crop protection

research, include seeds and plant biotechnology. The main
aim of research and development work in plant biotechnol-
ogy is to improve the agronomic characteristics and quality
of crop plants. The technologies employed in this area com-
prise all the tools required to improve important crops such
as cotton, canola and rice for producers and industry partners
– from the identification of a target gene to the development
of a plant.
Topical examples of active ingredients to emerge from research

at Bayer CropScience are:
• spirotetramat (lead brand: Movento®): systemic

insecticide for the control of a wide range of sucking
insects;
• pyrasulfotole (lead brand: Huskie®): herbicide effective
against a large number of broad-leaved weeds;
• thiencarbazone-methyl (lead brands: Adengo®, Cor-
vus®): active ingredient for weed control in corn and
cereals.
Best-selling products*
Atlantis®
Herbicide
Basta®/Liberty®/Rely®
Herbicides
Confidor®/Gaucho®/Admire®/Merit®
Insecticides
Decis®/K-Othrine®
Insecticides
Fandango®
Fungicide
Flint®/Stratego®/Sphere®/Nativo®
Fungicides
Folicur®/Raxil®
Fungicides
Poncho®
Seed treatment
Proline®/Input®/Prosaro®
Fungicides
Puma®
Herbicide

trifloxystrobin, a compound that
farmers all over the world have
been using for years to protect
their cereal, vegetable and fruit
crops against harmful fungal
diseases, also makes the plants
more resistant to stress factors
such as drought? Field trials show
that crops to which this substance
is applied give higher yields.
www.bayercropscience.com
24 Subgroups | Bayer MaterialScience
Bayer MaterialScience is a renowned supplier of high-perfor-

mance materials such as polycarbonates and polyurethanes,
and innovative system solutions for a wide range of everyday
uses. Products holding leading positions on the world market
account for a large proportion of the company’s sales.
The subgroup’s portfolio is divided into three business units

• Polyurethanes,
• Polycarbonates,
• Coatings, Adhesives, Specialties,
and the Industrial Operations area.
Sales of Bayer MaterialScience subgroup came in at €9.7 bil-
lion in 2008, down 6.7 percent from the prior year. Selling
price increases were more than offset by a drop in volumes.
The global financial and economic crisis impacted this sub-
group in nearly all product groups and regions. The Polycar-
bonates business unit had sales of €4.9 billion (-6.3 percent),
while those of Polyurethanes fell by 15.6 percent to €2.4 bil-
lion. Business in the Coatings, Adhesives, Specialties unit was
down 0.8 percent to €1.6 billion. Sales of Thermoplastic Poly-
urethanes* moved ahead 2.6 percent to €236 million. Sales in
Industrial Operations also grew by 15.6 percent to €489 mil-
lion.
ebitda before special items for 2008, at €1.1 billion, was below
the previous year. Over the year as a whole, price increases,
savings from the ongoing restructuring program and further
countermeasures adopted only partially offset the negative ef-
fects of lower volumes and higher raw material costs.
.
Corporate Data
Company name Bayer MaterialScience AG
Chairman of the
Board of Management Patrick Thomas
Business Units Polyurethanes
Polycarbonates
Coatings, Adhesives, Specialties
Thermoplastic Polyurethanes*
R&D expenses €221 million
Employees 15,100
* The Thermoplastic Polyurethanes business unit was integrated

into the Polyurethanes and Coatings, Adhesives, Specialties
business units effective April 1, 2009. Patrick Thomas,
of Management
Sales
€ million
2008 9,738
2007 10,435
Number of employees
Employees
2008 15,100
2007 15,400

€ million
2008 221
2007 209

26 Subgroups | Bayer MaterialScience

In 2008, Bayer MaterialScience spent €221 million on research
and development (not including joint development activities
with customers). This subgroup thus accounted for about 8 per-
cent of the Bayer Group’s total research and development ex-
penses.
In the Polyurethanes; Polycarbonates; and Coatings, Adhesives,

Specialties business units, the latest technologies and produc-
tion processes are used to develop new products and applica-
tions in close cooperation with customers and other external
partners.
Product development work in the Polyurethanes business unit

is focused on expanding applications for materials and optimiz-
ing the properties of polyurethane systems. In the construction
industry, for example, polyurethanes serve as the basis for
highly efficient insulating materials and thus make an active
contribution to climate protection.
Other examples from the company’s materials research in-

clude:
• holographic data storage media: development of data

storage media with a capacity of 300 gb per first-genera-
tion disc;
• polyurethane systems: new application of a polyure-
thane foam system in the production of railroad ballast
beds that reduce train noise levels;
• Functional Films: business unit for three-dimensionally
formable electroluminescent films (Lyttron©), lcd diffuser
films for flat screens etc.
The New Business section of MaterialScience constantly

tracks and evaluates new technological and market trends,
channeling the most promising ideas into research and
development projects in order to create profitable business
opportunities for the future or expand existing technology
platforms.
Principal products*
Bayblend®
Brand name for polymer blends based on polycarbonate and
acrylonitrile-butadiene-styrene
Baydur®
Polyurethane integral-skin foam for appliance housings, medical equipment, sports
goods, sanitary items and furniture
Bayflex®
Family of elastic polyurethane systems with customizable properties for a range of
applications
BaySystems®
Global polyurethane system partners
Baytubes®
Brand name for multi-wall carbon nanotubes
Desmodur®/Desmophen®
Raw materials for automotive and industrial coatings, anti-corrosion systems
and floor coatings
Desmopan®
Thermoplastic polyurethanes for a variety of high-tech applications
Makrolon®
Transparent, impact-resistant polycarbonate for CDs, DVDs, automotive
applications, architectural glazing, electrical and electronic applications
Multitec®
Innovative polyurethane spray system for the manufacture of large-area parts

Baytubes® carbon nanotubes from
Bayer MaterialScience are many times
stronger than steel but weigh much less?
They can be used for the rotor blades
of wind turbines, for example, making
them considerably lighter and increas-
ing their strength.
www.bayermaterialscience.com
28 Service Companies
Service Companies
The central service functions for the Bayer subgroups’

operations are organized into three service companies:
Bayer Business Services

Bayer Business Services is the Bayer Group’s international
competence center for it-based services. The focus of this
company’s offering is on integrated services in the core areas
of it infrastructure and applications, procurement and
logistics, human resources and management services, and
finance and accounting.

Bayer Technology Services is the global technological back-
bone and a major innovation driver for the Bayer Group. Its
services comprise the development, planning, construction
and optimization of processes and plants. This service com-
pany offers fully integrated solutions right through the life
cycle of production facilities.
Currenta
Currenta offers services for the chemical industry including
utility supply, waste management, infrastructure, safety,
security, analytics and vocational training. This service
company, a joint venture between Bayer and lanxess, oper-
ates the chempark sites in Leverkusen, Dormagen and
Krefeld-Uerdingen, Germany.
Corporate Data
Company name Bayer Business Services GmbH
Chairman of the
Executive Board Daniel Hartert°
Employees 5,460*
Services IT-based services
(as of December 31, 2008) ° effective January 1, 2009
www.bayerbbs.com
Daniel Hartert,
Chairman of the Executive Board
Corporate Data
Company name Bayer Technology Services GmbH
Managing Director Achim Noack
Employees 2,600**
Services Technology solutions
for processes, plants
and products
www.bayertechnology.com
Achim Noack, Managing Director
Corporate Data
Company name Currenta GmbH & Co. OHG
Chairman of the
Executive Board Klaus Schäfer
Employees 5,500***
Services Services for the chemical
industry; management and
operation of CHEMPARK
www.currenta.com Klaus Schäfer,

Chairman of the Executive Board
* number of employees in full-time equivalents, excluding local services and ex-trainee pool
** number of employees in full-time equivalents
*** number of employees in full-time equivalents, including employees of subsidiaries, excluding trainees
30 Research and Development
Research and
Development
In 2008 Bayer spent €2.7 billion on research and develop-
ment, focusing particularly on the development of new prod-
ucts to strengthen the core businesses. To achieve its growth
targets, the Group is endeavoring to steadily expand its prod-
uct portfolio and optimize its production processes. Research
activities are closely aligned to market requirements. Supple-
menting the company’s own r&d is an international network
of collaborations with leading universities, public-sector re-
search institutes and partner companies. By pooling expertise
in this way, Bayer aims to rapidly translate new ideas into
successful products. These activities are also supported by
the systematic advancement of talented scientists and experts
in the company’s research and development units.
Research in the three subgroups

Of the Group’s entire r&d expenditures, Bayer HealthCare ac-
counted for 66 percent, Bayer CropScience for 24 percent and
Bayer MaterialScience for 8 percent. Further information on
each subgroup’s r&d activities is provided in the respective
chapter of this brochure.

All Bayer subgroups work closely with Bayer Technology
Services worldwide on technology solutions, particularly in
the fields of process technology, plant engineering, automa-
tion and product development. For example, this service com-
pany cooperates with MaterialScience in the development of
new production processes that make efficient use of energy
and raw materials, thereby helping the subgroup to maintain
and expand its technological and cost leadership. Centralized
development work on technologies relevant to more than one
subgroup helps HealthCare and CropScience to shorten de-
velopment times for new products. International sourcing of
know-how plays a key strategic role in this respect. It involves
country-specific expertise in the implementation of capital
expenditure projects, global access to innovations and public
funding, and the recruiting of top international personnel.
Bayer Innovation
Bayer Innovation investigates and evaluates innovative areas re-
lated to the subgroups’ current core activities and develops them
into viable new businesses for the Bayer Group. An example is
the manufacture of medicines in plants (plant-made pharmaceu-
ticals, or pmp). In 2008 a pilot facility was inaugurated to produce
clinical trial samples of a vaccine for the therapy of non-Hodg-
kin’s lymphoma. Bayer Innovation also has activities in the field
of medical technology, with novel concepts under development
including dressings made from biodegradable silica gel fibers for
the treatment of chronic wounds. The full potential of these tech-
nologies is being evaluated in close cooperation with the Bayer
subgroups and external partners.
Investment in Research and Development

by Subgroup
Other
Bayer MaterialScience 2%
8%
Bayer HealthCare
66 %
Bayer CropScience
24 %
www.bayer.com > Research & Innovation

32 Employees
Employees
As of December 31, 2008 the Bayer Group employed 108,600

people worldwide, compared with 106,200 at the end of the
previous year. Personnel expenses declined in 2008 by
1.1 percent to €7.5 billion.
Training and development

The vocational training of young people represents a sustain-
able investment in the company’s future and at the same time
forms part of its social responsibility as a major employer. In
countries with dual training programs, Bayer offers places on
such programs. At the German sites alone, more than 900
young people embarked on vocational training programs in
2008 to prepare for a career. In Mexico more than 80 young-
sters entered dual training programs, in Argentina about 30
and in China more than 20.
The Group’s economic success is crucially dependent on a

high level of commitment by all employees. It is therefore
important to enhance employee skills and performance
through continuing education, global personnel development
programs and a healthy work environment. Flexible worktime
models enable employees to better harmonize professional
and personal interests. In November 2008, Bayer celebrated
the 20th anniversary of its program to assist and train disad-
vantaged youngsters. The company continued this initiative
last year, accepting 149 young people with educational defi-
cits into a twelve-month program. The company is working
with them at five sites in Germany to prepare them for a
formal vocational training program. As an inventor company,
Bayer relies on the ideas and potential of managerial staff
with an academic background. In Germany, for example,
some 300 university graduates in various disciplines were
hired in 2008. At the international level the number of em-
ployees with various academic qualifications joining Bayer
during the same period was over 1,000 in the United States,
more than 800 in China, nearly 100 in Japan, some 400 in
Brazil and about 300 in Mexico.
Sharing in the company’s success

Ensuring that employees share financially in its success has long
been a firm feature of Bayer’s human resources policy. For 2008
Bayer employees received a total of €475 million in variable
payments under the Group-wide short-term incentive (sti) pro-
gram.
Realigning the human resources function

Since 2006 Bayer has been gradually realigning its human
resources function by way of the Group-wide “Transforming
Human Resources” project. The goal is to increase the contribu-
tion of the human resources function to the success of the busi-
ness and enhance the quality and efficiency of the Group-wide
human resources processes. In January 2009, Bayer Schering
Pharma also aligned its human resources activities to the new
structures. In 2008, five central human resources processes were
integrated into the new operating model in more than 70 coun-
tries and over 160 Group companies according to uniform rules
and procedures.
Employees by Function*
Administration
9,200 Production
49,100
Research
12,300
Marketing
38,000
* employees by region see page 35 www.mybayerjob.com

34 Sustainability and Commitment
Sustainability and
Commitment
The essence of Bayer’s sustainability concept is to achieve
lasting success in its business activities in harmony with so-
cial needs and objectives. Sustainability features prominent-
ly in the company’s mission statement and its Values and
Leadership Principles. This is complemented by a Sustainable
Development Policy, a stated position on human rights and a
commitment to the principles of the u.n. Global Compact and
the Responsible Care Global Charter.
Performance indicators
Performance indicators are a key feature of sustainability man-
agement. In 2008 Bayer maintained or improved its perfor-
mance in terms of most of the indicators (see table). However,
there was an increase in major environmental incidents. The
Group is analyzing and evaluating each of these incidents in
order to take the necessary action. Emissions of volatile organic
compounds rose due to an increase in production at one of the
Group’s sites in Asia.
Climate protection
Bayer places special importance on climate protection. The
purpose behind the Group-wide Bayer Climate Program, ini-
tiated by the Group Management Board and launched in
2007, is to further reduce greenhouse gas emissions from its
production processes and develop new solutions for climate
protection and dealing with climate change. Bayer is also
pooling its own specific competencies to drive forward this
climate protection program and has already initiated ground-
breaking “lighthouse” projects:
• the EcoCommercial Building – a global concept for a

zero-emissions building in the office and industry sector;
• the development of stress-tolerant plants;
• the Bayer Climate Check for production processes.
Performance Indicators
Category Key Performance Indicator 20076 2008
Health, Safety
and Environment
Health and safety Industrial injuries to Bayer employees
resulting in at least one day’s absence7 2.4 2.2
Reportable industrial injuries to
Bayer employees7 3.7 3.6
Major environmental incidents 3 9*
Transportation incidents 10 10
Emissions Direct greenhouse gas emissions
(CO2 equivalents in million metric tons)8 4.4 4.0
Indirect greenhouse gas emissions
(CO2 equivalents in million metric tons)8 3.7 3.5
Volatile organic compounds
(VOC) (thousand metric tons / year) 2.9 3.2
Total phosphorus in waste water
(thousand metric tons / year) 1.0 0.8
Total nitrogen in waste water
Total organic carbon (TOC)
Waste Hazardous waste generated
(million metric tons / year) 0.3 0.4
Hazardous waste landfilled
(million metric tons / year) 0.1 0.1
Use of resources Water use (million m / d)
3
1.2 1.2
Energy use (petajoules
[1015 joules]) / year) 91.7 88.5
Employees and Society

Diversity and opportunity Percentage of women in senior
management 4.3 4.7
Number of nationalities in senior
management 16 23
Training and development Training costs in % of
personnel expenses 2.0 2.7
Employment Number of employees by region9**
Europe 56,200 55,500
North America 16,800 17,000
Asia / Pacific 18,900 20,800
Latin America / Africa / Middle East 14,300 15,300
* figure in the Annual Report 2008 amended in light of subsequent knowledge

** employees by function see page 33
2008 figures restated; for footnotes see page 44
36 Sustainability and Commitment
Sustainable investment
For many years Bayer stock has been included in major indi-
ces and represented in investment funds that focus on com-
panies with sustainable and responsible corporate policies.
The Bayer Group has been featured in the Dow Jones Sustain-
ability Index World (djsi World) since 1999. It has also been
continuously listed in the ftse4Good index series. In 2007,
Bayer was included in the new ftse4Good Environmental
Leaders Europe 40 Index. The analysts of the Storebrand
Principle Fund rate Bayer among the top companies in its
peer group, awarding it the ranking “Best in Class – Environ-
mental and Social Performance.” In addition, Bayer has been
listed in the French “Advanced Sustainable Performance In-
dices” (aspi) Eurozone Index since 2001. In 2008 the Carbon
Disclosure Project (cdp), an investors’ organization, again
listed Bayer in the Climate Disclosure Leadership Index – the
first global climate protection index – as one of the world’s
leading companies in the area of climate protection. Bayer is
the only European chemical and pharmaceutical company to
have been listed in this index four times in succession.
Corporate social responsibility

Throughout the world Bayer supports some 300 social proj-
ects in the fields of education, environment, health, sports
and culture. In 2008 the Bayer Science & Education Founda-
tion provided a total of about €500,000 in funding for
47 science projects in schools near the company’s sites in
Germany. In 2008, as part of the Bayer Climate Program, the
Foundation presented the new Bayer Climate Award for the
first time to emeritus Professor Eberhard Jochem of the
Fraunhofer Institute for Systems and Innovation Research in
Karlsruhe. In this way Bayer honored the scientist for his
groundbreaking contributions to the improvement of energy
efficiency, which is essential for reducing greenhouse gas
emissions. The Bayer Climate Award is the first international
prize for outstanding achievements in fundamental climate
science research. In 2008 Bayer and the United Nations En-
vironment Programme (unep) again organized around a
dozen environmental projects for young people and children
within the scope of their global environmental education part-
nership.
Selected Memberships
Responsible Care Global Charter
One of the first signatories to the chemical industry’s global
charter for sustainable development and Responsible Care
The Global Compact
Founding member of the U.N. corporate responsibility
initiative for a sustainable world
World Business Council for Sustainable Development
Active member since 1997
“econsense” – Forum for Sustainable Development of
German Business
Founding member of the pan-sectoral initiative for
sustainable development
3C: Combat Climate Change
Founding member of the global climate protection initiative
Global Business Coalition on HIV / AIDS,
Tuberculosis and Malaria
Member of the global corporate network for the fight against
these three epidemic diseases
Selected Projects
Global Exploration Fund
Bayer set up the Global Exploration Fund together with
National Geographic, the world’s largest non-profit scientific
organization. Since 2007 this fund has supported nine
research projects aimed at protecting the quality of drinking
water worldwide.
“Making Science Make Sense”
In 2008 Denmark joined the list of countries participating
in the “Making Science Make Sense” education program.
Schoolchildren in a total of eleven countries are now
benefiting from the voluntary commitment of Bayer
employees who visit schools to demonstrate the aims and
benefits of science with the aid of hands-on experiments.
Young Environmental Envoys
In 2008 another country – South Africa – was added to
the “Young Environmental Envoy” program. A total of 18
countries in Asia, Latin America, Africa and Europe now
send delegates on a week-long study trip to Germany at
Bayer’s invitation once a year.
For more information, go to:

www.sustainability.bayer.com
www.climate.bayer.com
www.csr.bayer.com
38 History
History
1863 On August 1, businessman Friedrich Bayer and
master dyer Johann Friedrich Weskott establish a
dyestuffs factory in Barmen, now part of the city of
Wuppertal.
1865 The company founders purchase an interest in a

coal tar dye factory in the United States and begin
exporting intermediates.
1876 A branch factory is opened in Moscow.
1881 On July 1, the descendants of Bayer and Weskott

establish the joint stock company Farbenfabriken
vorm. Friedr. Bayer & Co.
1884 The chemist Carl Duisberg starts his career at Bayer.

Under his leadership, the scientists make pioneering
discoveries.
1888 The company establishes a pharmaceutical

department.
1891 The Leverkusen site is purchased.
1897 Bayer scientist Dr. Felix Hoffmann succeeds in

synthesizing a chemically pure and stable form of
acetylsalicylic acid, the active ingredient of Aspirin®.
1899 Aspirin® is registered as a trademark and sets out to

become the world’s favorite painkiller.
1912 The company’s headquarters are transferred to

Leverkusen.
1925 Farbenfabriken vorm. Friedr. Bayer & Co. merge with

other companies to form I.G. Farbenindustrie AG. As
Germany’s most important chemical company, I.G.
Farbenindustrie also becomes involved in the events
of the Third Reich. After the Second World War, the
Allies seize and subsequently break up the I.G.
Farben.
1939 Bayer scientist Gerhard Domagk is awarded the

Nobel Prize for Medicine for his discovery of the
antibacterial effects of sulfonamides (Prontosil).
1951 Bayer is re-established as Farbenfabriken Bayer AG

(changing its name to Bayer AG in 1972).
1973 Ground is broken for the Brunsbüttel production site

and six years later, in 1979, for the Agricultural
Center (now the corporate headquarters of Bayer
CropScience) in Monheim.
1986 Bayer’s entire u.s. activities are consolidated under

the management holding company Bayer usa Inc.,
Pittsburgh.
1991 Bayer’s Communication Center (BayKomm) is

inaugurated in Leverkusen.
1994 The first production facility of Bayer Bitterfeld GmbH

comes on stream. In the same year, Bayer acquires the
North American self-medication business of Sterling
Winthrop, at the same time regaining full rights to the
Bayer name for all products and the Bayer Cross
trademark in the United States and Canada, which had
been confiscated after the First World War.
1999 To mark the 100th birthday of Aspirin® on March 6,

professional mountaineers wrap Bayer’s former
high-rise headquarters building in Leverkusen,
transforming it into the world’s biggest Aspirin® pack
and earning the company three entries in the
Guinness Book of Records.
2000 Acquisition of the polyols business of Lyondell

Chemical Company, United States, makes Bayer the
world’s biggest producer of raw materials for
polyurethanes.
2001 Bayer acquires Aventis CropScience for €7.25 billion,

making it a world leader in crop protection. On
December 6, the company’s management announces
plans to establish independent operating subsidiaries
under the umbrella of a management holding
company.
2002 Bayer CropScience AG is launched in October as the

first legally independent Bayer subgroup.
40 History
2003 In February, the World Health Organization (who)

includes acetylsalicylic acid, the active ingredient in
Aspirin®, in its “List of essential medicines.”
2003 In October, the subgroups Bayer Chemicals AG and

Bayer HealthCare AG and the service company Bayer
Technology Services GmbH gain legal independence
as part of the reorganization of the Bayer Group. The
subgroup Bayer MaterialScience AG and the service
companies Bayer Business Services GmbH and Bayer
Industry Services GmbH & Co. OHG follow in
December.
2004 In January the Group’s world-famous trademark, the

Bayer Cross, celebrates its centennial.
2004 In June, Bayer becomes the first private-sector

partner to the United Nations Environment Pro-
gramme (unep) in the area of youth and environment.
2005 In January, Bayer completes the acquisition of the

Roche consumer health business, advancing to
become one of the world’s top three suppliers of
non-prescription medicines.
2005 Lanxess AG is spun off from the Bayer Group on

January 28. This company continues Bayer’s
chemicals business and parts of its polymers
business.
2005 In December, the u.s. Food and Drug Administration

approves sorafenib (tradename: Nexavar®), an active
ingredient jointly developed by Bayer HealthCare and
Onyx Pharmaceuticals Inc., for the treatment of
advanced renal cell carcinoma.
2006 In March, Bayer announces a public takeover offer

for Schering* AG, Berlin, Germany. In July, Bayer
gains control of 92.4 percent of the approximately
191 million outstanding Schering* shares. In
December, Schering* AG is officially renamed Bayer
Schering Pharma* AG. The company is headquar-
tered in Berlin.
2007 In January, Bayer sells the Diagnostics Division of

Bayer HealthCare to Siemens AG, Munich, for
€4.2 billion.
2007 In March it is announced that the BayArena stadium,

home of German Bundesliga soccer team Bayer 04
Leverkusen, is to be modernized and enlarged to
accommodate a crowd of over 30,000.
2007 In May, Bayer announces that its high-rise former

headquarters building is to be converted into one of
the world’s largest media facades. Completion is
scheduled for 2009.
2007 In August, Bayer hosts the tunza International Youth

Conference of the United Nations Environment
Programme (unep) in Leverkusen, the first time this
youth environmental summit has been held in central
Europe. 180 young people from 85 countries debate
global environmental issues.
2007 Centennial celebration: in September, the 100th

season of the Bayer Cultural Affairs Department gets
under way.
2007 November sees the launch of the integrated,

Group-wide Bayer Climate Program. The program’s
goals include a further reduction in co2 emissions
from Bayer’s production facilities.
2008 In June Bayer is presented with the 2008 Environ-

mental Award in the category “Environmentally
Friendly Technologies” by the Federation of German
Industries (bdi). Use of the new oxygen-depolarized
cathode technology reduces power consumption and
co2 emissions.
2008 The squeeze-out of the minority stockholders of

Bayer Schering Pharma* AG is effected in September.
At the turn of the year 2008/2009 the pharmaceuti-
cals businesses of Bayer and Bayer Schering Pharma*
in Germany are combined in a single legal entity.
2008 In October the world’s largest mdi production facility

goes on stream in Shanghai.
2008 In November, Bayer and the German Cancer

Research Center form a strategic research alliance
scheduled to run for an initial period of two years.
www.bayer.com > Bayer Group > History
* The names “Bayer Schering Pharma” or “Schering” as used in this publication always refer to Bayer Schering
Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.
42 Dialogue
Dialogue
Bayer places great importance on communication, regarding

it as a company’s duty to society and at the same time an
essential tool for shaping its public image. Bayer seeks an
open dialogue on people’s questions and problems in order
to ensure credibility, trust and acceptance.
Print and online publications

Bayer AG issues a range of publications to keep the general
public, employees and stockholders abreast of develop-
ments:
• Annual Report
• Stockholders’ Newsletter
• Sustainable Development Report
• research (scientific magazine)
• report (company magazine)
• direkt (newspaper for employees/neighbors)
A comprehensive overview of the Bayer Group and its global

activities can also be found on the company’s Internet site at
www.bayer.com, which also contains an innovative Podcast
Center with a range of audio and video clips. Further informa-
tion on the subgroups and service companies is provided on
their respective homepages.
BayKomm
Another focus of the company’s information offering is the
Bayer Communication Center “BayKomm” in Leverkusen,
which was opened in 1991. BayKomm features exhibition ar-
eas and numerous events devoted to specific subjects. Visitors
can learn about Bayer’s activities and acquaint themselves with
a variety of scientific topics – from the development of new
medicines and the safeguarding of global harvests to modern
materials that contribute to climate protection. Also on offer
are guided tours to the approximately 300 exhibits, experi-
mental lectures and projects for school students.
Contact
Bayer AG:
Dr. Katrin Schneider, email: katrin.schneider.ks@bayer-ag.de
Bayer HealthCare:
Dr. Markus Pickel, email: markus.pickel@bayerhealthcare.com
Bayer CropScience:
Steffen Kurzawa, email: steffen.kurzawa@bayercropscience.com
Bayer MaterialScience:
Dr. Frank Rothbarth, email: frank.rothbarth@bayermaterialscience.com
Bayer Business Services:
Oliver Günther, email: oliver.guenther@bayerbbs.com
Bayer Technology Services:
Dr. Arnold Rajathurai, email: arnold.rajathurai@bayertechnology.com
Currenta:
Jürgen Gemke, email: juergen.gemke@currenta.de
Internet addresses
Homepage www.bayer.com
BayKomm www.baykomm.bayer.com
Annual Report www.annualreport.bayer.com
Stockholders’ Newsletter www.stockholders-newsletter.bayer.com
Sustainable Development
Report www.sd.bayer.com
Scientific magazine “research” www.research.bayer.com
Publications www.publications.bayer.com
News releases www.press.bayer.com
Podcast Center www.podcast.bayer.com
To order print publications:

Email serviceline@bayer-ag.de
Regular mail Please use the attached reply card
Communication Center “BayKomm”

Kaiser-Wilhelm-Allee, 51368 Leverkusen
Opening times for visitors without an appointment:
Monday through Friday 12.00 noon to 6.00 p.m.
Sunday 12.00 noon to 5.00 p.m.
Other times by appointment
BayKomm Service Infoline:

Phone +49 214 30 50100
44
1 EBIT plus amortization of intangible assets and depreciation of property,

plant and equipment. EBITDA, EBITDA before special items and EBITDA
margin are not defined in the International Financial Reporting Standards
and should therefore be regarded only as supplementary information. The
company considers EBITDA before special items to be a more suitable
indicator of operating performance since it is not affected by depreciation,
amortization, write-downs/write-backs or special items. The company also
believes that this indicator gives readers a clearer picture of the results of
operations and ensures greater comparability of data over time. The
underlying EBITDA margin is calculated by dividing underlying EBITDA by
sales.
2 EBIT as shown in the income statement
3 Earnings per share as defined in IAS 33 = net income divided by the average
number of shares
4 Gross cash flow = income from continuing operations after taxes, plus income
taxes, plus/minus non-operating result, minus income taxes paid or accrued,
plus depreciation, amortization and write-downs, minus write-backs, plus/
minus changes in pension provisions, minus gains/plus losses on retirements
of noncurrent assets, plus non-cash effects of the remeasurement of acquired
assets. The change in pension provisions includes the elimination of non-cash
components of the operating result. It also contains benefit payments during
the year.
5 Net cash flow = cash flow from operating activities according to IAS 7
6 excluding Diagnostics, H. C. Starck and Wolff Walsrode
7 number of injuries per million hours worked
8 as per Greenhouse Gas Protocol
9 permanent and temporary employees in full-time equivalents

Bayer Names | Figures | Facts 45 5
Masthead
Published by
Bayer AG, Communications, 51368 Leverkusen, Germany
Editor
Dr. Katrin Schneider, phone +49 2 14 30 4 88 25
Email: katrin.schneider.ks@bayer-ag.de
English edition
Currenta GmbH & Co. OHG
Language Service
Bayer on the Internet

www.bayer.com
April 2009
Forward-Looking Statements
This publication contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could
lead to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those described in Bayer’s published
reports, which are available on the Bayer website at www.bayer.com. The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
Important information
The names “Bayer Schering Pharma” or “Schering” as used in this publi-
cation always refer to Bayer Schering Pharma AG, Berlin, Germany, or its
predecessor, Schering AG, Berlin, Germany, respectively.
Editon 2009/2010 • E 910 831 854
Science For A Better Life

Bayer Names Figures Facts 2009 2010

Enviado por

Dados do documento

Descrição original:

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Bayer Names Figures Facts 2009 2010

Enviado por

Direitos autorais:

Formatos disponíveis

Names | Figures | Facts

Sites and Regions 6

Supervisory Board, Corporate Governance 10

Subgroups and Service Companies

Research and Development 30

Sustainability and Commitment 34

We are firmly aligned to our mission statement “Bayer:

As an inventor company, we plan to continue setting trends

Our expertise and our products are helping to diagnose, al-

We are committed to the principles of sustainable develop-

We seek to retain society’s confidence through performance,

www.bayer.com > Bayer Group > Mission Statement

Bayer AG headquarters in Leverkusen

Bayer AG defines common values, goals and strategies for

Group Management Board

Chairman Werner Wenning

Finance Klaus Kühn

Innovation, Technology Wolfgang Plischke

Corporate Center Departments

Chairman Arthur J. Higgins

Chairman Friedrich Berschauer

Chairman Patrick Thomas

Bayer Business Services

Chairman of the Executive Board Daniel Hartert

Bayer Technology Services

Managing Director Achim Noack

Chairman of the Executive Board Klaus Schäfer

Sites and Regions

The Bayer Group is a

Latin America/Africa/Middle East

www.bayer.com > Bayer Group > Bayer Worldwide

Dr. Wolfgang Plischke

Dr. Richard Pott

The Supervisory Board has set up four committees – the Pre-

Members of the Supervisory Board

Vice Chairman of the Supervisory Board

Other members of the Supervisory Board

www.bayer.com > Bayer Group > Supervisory Board

In 2008 Bayer had a successful year overall in an increas-

Gross cash flow increased by 10.7 percent from the previous

Bayer Group Key Data

Sales 32,385 32,918 1.6

* as per segment table in the Annual Report 2008

Current information on business developments will be found on the Internet at:

Caught up in the global market turbulence, Bayer stock lost

The price initially fell by some 25 percent at the start of the

German stock market

The downward movement was triggered by the subprime

Dividend per share

Comparative performance of Bayer stock

Bayer DJ EURO STOXX 50SM DAX

Dividend per share (€)

Bayer HealthCare is among the world’s foremost innovators

The subgroup has four operating divisions:

• Animal Health (veterinary medicines and grooming

Sales of the Bayer Schering Pharma Division increased by

Research and development expenses

Current information on business developments will be found on the Internet at

Research and development activities

The Bayer Schering Pharma* Division carries out research

• Xarelto®: Drug product for the prevention and treatment

Research and development activities in the Consumer Care

Research in the Medical Care Division is directed mainly to-

* The Thermoplastic Polyurethanes business unit was integrated